STAT+: Eli Lilly ends 340B drug discounts to some hospitals for failing to provide claims data

Eli Lilly began eliminating mandated price breaks on drugs to several dozen hospitals on February 1, 2024, citing their failure to provide comprehensive claims data. This action follows a company warning issued earlier in the month, which was part of a broader policy announced in January aimed at reducing what Eli Lilly describes as duplicate discounts paid to hospitals. Hospital trade groups have contested this move, deeming it unlawful and seeking congressional intervention. Eli Lilly stated that over 2,300 hospitals had complied with its data request, but some larger hospital systems refused. As of the policy's effective date, approximately 1,000 hospitals had not complied, and Eli Lilly was actively pursuing data from about 50 larger institutions. The company's policy aims to ensure accurate reporting and prevent financial discrepancies related to the federal 340B drug discount program.